We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > OTL-300

News List

Orchard Announces Publication by San Raffaele-Telethon Institute for Gene Therapy of OTL-300 Clinical Data for the Treatment of Transfusion-Dependent Beta-Thalassemia in Nature Medicine b3cnewswire
January 23, 2019
Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies....
PRIME status for Orchard’s gene therapy pharmatimes
October 11, 2018
The European Medicines Agency has granted Orchard Therapeutics’ experimental gene therapy OTL-300 PRIME designation as a potential treatment for the most severe form...